NSABP Members' Area
  Password Protected - Access
  Limited to NSABP Participating
  Institutions Only


NSABP Foundation, Inc.



General NSABP Information
  Financial Conflicts of
     Interest Policy
  Coalition Comment:
     Reconfiguration
  IOM Report Group Comment
  Contact the NSABP
  Pathology Section
  Future Meetings
  NSABP Newsletters
  Media Info on STAR
  Employment

Clinical Trials Information
  Clinical Trials Overview
  Protocol Chart
  Never Say Lost

Treatment Trials Information
  Protocol B-43
  Protocol B-47
  Protocol B-51

Prevention Trials Information
  Protocol P-1 - BCPT
  Protocol P-2 - STAR
  Protocol P-5
  BreastCancerPrevention.com

Scientific Publications

Related Web Sites



Medical Search Engines



To report problems, ask
questions or make comments,
please send e-mail to:
Webmaster@nsabp.pitt.edu

NSABP Clinical Trials Overview


Protocol C-10
A Phase II Trial of 5-Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) Chemotherapy Plus Bevacizumab for Patients with Unresectable Stage IV Colon Cancer and a Synchronous Asymptomatic Primary Tumor

Specific Aims
Primary Aim
To determine the rate of major morbidity for patients who are treated with mFOLFOX6 + bevacizumab without resection of the primary tumor. Major morbidity is defined as any event related to the intact primary tumor necessitating surgery or resulting in patient death.

Secondary Aim
Local Complications
To determine the rate of specific events related to the intact primary tumor requiring hospitalization or a major intervention but not requiring surgery.

Serious Adverse Events Related to Study Therapy
To determine the rate of ≥ grade 3 toxicity as defined by the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0) that is related to study therapy prior to disease progression.

To determine overall survival.